Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3596920

Nc1cccc(F)c1F.O=C(O)C(F)(F)F

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CES1 P23141 4/20 0.44
CES2 O00748 3/20 0.44
BCHE P06276 1/20 0.44
ALB P02768 1/20 0.37
MMP2 P08253 1/20 0.37
KCNN4 O15554 2/20 0.36
PTGS1 P23219 2/20 0.36
HDAC1 Q13547 2/20 0.36
TTR P02766 1/20 0.35
HPGD P15428 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CHIT1 Q13231 1/20 0.35
HDAC3 O15379 1/20 0.34
MAPK1 P28482 1/20 0.34
HDAC2 Q92769 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL15568892 0.82 CES1 (0.43) CES1CES2BCHEALBKCNN4
Trifluoroacetic Acid SCHEMBL3783854 0.81 MMP2 (0.52) CES1CES2BCHEALBMMP2
SCHEMBL31167436 0.81
SCHEMBL59477 0.81
Hydrochloric Acid SCHEMBL22263487 0.79 CYP3A4 (0.41) CES1CES2BCHEHPGDL3MBTL1
Methane SCHEMBL27494474 0.79 ALDH1A1 (0.41) CES1CES2BCHEHPGDL3MBTL1
Trifluoroacetic Acid SCHEMBL3596917 0.78 CES2 (0.55) CES1CES2BCHEALBKCNN4
Sulfuric Acid SCHEMBL8667555 0.78 CES2 (0.43) CES1CES2BCHEHDAC1TTR
Trifluoroacetic Acid SCHEMBL12480286 0.78 MPL (0.43) L3MBTL1
Phenol SCHEMBL27858331 0.76 CA12 (0.46) CES1CES2BCHEALBMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121612-B1 HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2014-10-01 EP disclosed
US-8299102-B2 Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals SANOFI (FR) 2012-10-30 US disclosed
US-20100016278-A1 HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2010-01-21 US disclosed
EP-2121612-A1 HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS Sanofi-Aventis (FR) 2009-11-25 EP disclosed
WO-2008080511-A1 HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2008-07-10 WO disclosed
EP-1942104-A1 Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals sanofi-aventis (FR) 2008-07-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016278-A1 HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS PTGIS, TBXAS1, EDNRA CES1 68/4885CES2 98/4885BCHE 370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.